Phase I study of the oral platinum agent satraplatin (JM-216) in combination with docetaxel in treatment of advanced malignancies.

Trial Profile

Phase I study of the oral platinum agent satraplatin (JM-216) in combination with docetaxel in treatment of advanced malignancies.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 23 Mar 2012

At a glance

  • Drugs Satraplatin (Primary) ; Docetaxel
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Agennix AG
  • Most Recent Events

    • 23 Mar 2012 Actual patient number (28) added as reported by ClinicalTrials.gov.
    • 23 Mar 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 09 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top